

Short-Communication

***In vitro* antibacterial activity of curcumin-meropenem combination against extensively drug-resistant (XDR) bacteria isolated from burn wound infections**

Javad Yasbolaghi Sharahi¹, Zahra Aliakbar Ahovan¹, Donya Taghizadeh Maleki¹, Zahra Riahi Rad¹, Zohreh Riahi Rad¹, Mehdi Goudarzi¹, Aref Shariati², Narjess Bostanghadiri¹, Elham Abbasi¹, Ali Hashemi^{1,*}

¹Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Article history:

Received: Jan 16, 2019

Received in revised form:

Feb 06, 2019

Accepted: Mar 29, 2019

Vol. 10, No. 1, Jan-Feb 2020, 3-

10.

*** Corresponding Author:**

Tel: +98-21-2387 2556

Fax: +98-21-2387 647

ali.hashemi@sbmu.ac.ir

Hashemi1388@yahoo.com

Keywords:

Curcumin

Meropenem

Extensively drug-resistant (XDR)

Antibacterial

Wound Infections

Abstract

Objective: Burn wound infection is a severe complication of thermal injury. Patients with severe burn injuries need urgent care to diminish complications after severe burns. Wound infections are commonly considered one of the most serious burn complications, particularly those that are caused by extensively drug-resistant (XDR) bacteria with few therapeutic choices. The objective of this study was to determine *in vitro* activity of meropenem and curcumin, alone and in combination, against antibiotic-susceptible Gram-positive, and antibiotic-resistant and antibiotic susceptible gram-negative bacteria isolated from burn wound infections.

Materials and Methods: The antimicrobial activity of meropenem and curcumin was investigated alone and in combination, against antibiotic-susceptible and antibiotic-resistant bacterial (XDR) strains isolated from burn patients. In addition, the cytotoxic effect of curcumin on human's epithelial cell lines, was determined.

Results: In this study, minimum inhibitory concentrations of meropenem decreased considerably in the presence of curcumin (2- to 16-fold reductions), with synergy observed. Curcumin exerted no cytotoxic effect at concentrations 256-512 µg/ml on human epithelial cell lines.

Conclusion: We suggest that curcumin-antibiotic combinations may provide an alternative approach for treating infections with multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria.

Please cite this paper as:

Yasbolaghi Sharahi J, Ahovan ZA, Taghizadeh Maleki D, Riahi Rad Z, Riahi Rad Z, Shariati A, Bostanghadiri N, Goudarzi M, Abbasi E, Hashemi A. *In vitro* antibacterial activity of curcumin-meropenem combination against extensively drug-resistant (XDR) bacteria isolated from burn wound infections. Avicenna J Phytomed, 2020; 10(1): 3-10.

Introduction

Among the most prevalent and hazardous forms of trauma, burns can be singled out as a gravely traumatic experience. Patients with serious thermal injuries need urgent

specialized care to reduce morbidity and mortality risks. In severely burnt patients, more than 75% of all deaths correspond to sepsis resulting from burn-wound infections or other complications (Church

et al., 2006). These infections are usually caused by bacteria such as *Streptococcus pyogenes*, *Staphylococcus aureus*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, vancomycin-resistant *Enterococci*, and *Escherichia coli* (Betts et al., 2016). The broad spectrum of antimicrobial resistance in multi-drug resistant (MDR) and extensively drug-resistant (XDR) isolates has significantly limited effective therapeutic options (Hirsch & Tam, 2010), resulting in longer hospital stays, and higher economic burden and morbidity and mortality rates (Chew et al., 2017). Carbapenems and colistin remain part of the last-resort antibiotics for dealing with MDR Gram-negative bacteria (Chew et al., 2017). Carbapenem-resistant Gram-negative bacteria are of growing concern and have rapidly spread worldwide (McLaughlin et al., 2013). Carbapenemases mediate one of the mechanisms that confer resistance to carbapenems and have become an important cause of antibiotic resistance. A large number of carbapenemases has been detected and classified into Ambler class A (GES, KPC, NMC, IMI, and SME), class B (IMP, GIM, VIM, NDM, and SPM SIM), and class D (OXA-48) (Chiu et al., 2018). Thus, the worldwide increasing number of carbapenemase-producing bacteria has resulted in the growing use of colistin with the unavoidable risk of emerging resistance (Liu et al., 2016). Recently, Yi-Yun Liu et al. reported the emergence of plasmid-mediated colistin resistance involving *mcr-1* gene from *Klebsiella pneumoniae* and *Escherichia coli* isolates from food, animals, and humans in China (Suzuki et al., 2016). Therefore, antibacterial resistance is a serious challenge in treating burn wound bacterial pathogens, and new approaches should be applied to reduce the deaths associated with bacterial infections in burn injuries. Curcumin was first shown to have antibacterial activity in the late 1940's. It was shown afterwards that this polyphenol possesses hypoglycemic, anti-inflammatory, wound-healing, and

antioxidant activities. Extensive preclinical studies over the last decades have indicated the therapeutic capabilities of curcumin against many human diseases (Gupta et al., 2013). A combination of curcumin and other antimicrobials has proven effective in combating MDR bacteria, e.g. *A. baumannii* (Betts et al., 2016). This study investigated the *in-vitro* activity of meropenem and curcumin, alone and in combination, against antibiotic-susceptible Gram-positive (*Enterococcus faecalis*) and antibiotic-resistant and susceptible Gram-negative (*A. baumannii*, *E. coli*, *P. aeruginosa*, and *K. pneumoniae*) isolated from burn wound infections.

Materials and Methods

Bacterial strains and media

Six *P. aeruginosa* positive for (*bla*_{GES}, *bla*_{PER-1}, *bla*_{VEB}, *bla*_{IMP}, and *bla*_{VIM} genes), four *A. baumannii* positive for (*OXA-51*, *OXA-24*, *OXA-23*, and *OXA-58* genes) and four *K. pneumoniae* positive for (*DHA*, *CTX-M*, *NDM-1*, and *NDM-6* genes) were isolated from wound exudate of burn patients admitted to the Burn Unit of Shahid Motahari Hospital in Tehran, Iran (2015-2017). All clinical isolates were XDR. Four standard strains, including *K. pneumoniae* ATCC 700603, *A. baumannii* ATCC19606, *P. aeruginosa* PAO1, *E. coli* ATCC25922, and *E. faecalis* ATCC29212, were also included in the study. The bacterial isolates were identified using conventional biochemical tests. All the bacteria isolated from burn patients, were subjected to antimicrobial susceptibility testing against commonly used antibiotics using disc diffusion method at minimum inhibitory concentration (MIC), according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (Wayne, 2011). *E. coli* ATCC 25922 and *P. aeruginosa* ATCC 27853 were used as control strains in antimicrobial susceptibility testing. Curcumin (purity>65%) was obtained from Sigma-Aldrich (St. Louis, MO, USA), and antibacterial disks were purchased from

Antibacterial activity of curcumin-meropenem combination

Mast (Diagnostics- UK). Polymyxin E and meropenem powders from Sigma-Aldrich (St. Louis, MO).

Detection of β -lactamase genes by PCR and Sequencing

OXA-type carbapenemases are a major player in carbapenem resistance in clinical isolates of *A. baumannii* and they are encoded mostly by *bla*OXA-23-type, *bla*OXA-24-type, *bla*OXA-51-type, and *bla* OXA-58-type. To determine the presence of the OXA-type carbapenemase-encoding genes in the clinical isolates, a multiplex PCR method was performed, as described. (Mohammadi et al., 2017). Also, PCR and sequencing methods were used to screen the presence of *bla*_{IMP}, *bla*_{VIM}, *bla*_{SPM}, *bla*_{KPC}, *bla*_{GIM}, *bla*_{DIM}, *bla*_{BIC}, *bla*_{OXA-48}, *bla*_{GES}, *bla*_{VEB}, *bla*_{DHA}, *bla*_{CTX-15} and *bla*_{NDM} genes in the isolates. PCR protocol used in this study was previously described (Mohammadi et al., 2017, Fallah et al., 2014). Amplification was performed in a thermal cycler (Eppendorf, Master cycler gradient). PCR product bands were analyzed after electrophoresis on 1.5% agarose gel at 100 V for 35 min in 1X Tris/Borate/EDTA (TBE) containing ethidium bromide under UV irradiation.

Antimicrobial susceptibility testing

MIC values for meropenem and curcumin were determined alone and in combination versus fourteen clinical isolates associated with burn wound infections and standard strains of Gram-negative and Gram-positive bacteria. Curcumin was diluted with 2% Dimethyl sulfoxide (DMSO) to yield concentrations ranging from 2 to 512 μ g/ml. Checkerboard assay was carried out on 96-well microtiter plate, inoculated with MHB broth containing 5×10^5 colony-forming units/ml of each isolate. Following 24 hr of incubation at 37°C, checkerboard assays results were recorded. The indices of fractional inhibitory concentration were assessed on the basis of the previously described method, according to which,

$FIC_a = MIC$ of compound a + compound b / MIC of compound a, $FIC_b = MIC$ of compound b + compound a / MIC of compound b, and $FIC_s = FIC_a + FIC_b$. $FICIs \leq 0.5$ were regarded as synergistic, values $>0.5-4.0$ as additive, and those >0.4 as antagonistic effects (Betts et al., 2016). All experiments were conducted in triplicates. The results are presented as mean.

Time-kill assays

This study employs time-kill assays to investigate and determine the antibacterial activity of mono- and combination therapies against *bla*_{IMP} harboring *P. aeruginosa* and *bla*_{NDM-1} harboring *K. pneumoniae* over a period of 24 hr. A 1/1000 dilution of an overnight culture (16 hr in Mueller-Hinton broth) (approximately 10^6 CFU/ml) was utilized as the starting inoculum (10 ml in universal tubes) prior to adding curcumin ($\times 1$ MIC), meropenem ($\times 1$ MIC), or the combination ($\times 1$ MIC curcumin: $\times 1$ MIC meropenem). Cultures were incubated at 37°C for 24 hr under continuous agitation (Betts et al., 2016). At the intervals of 0, 2, 4, 6, and 24 hr post-inoculation, 100 μ l of the samples was collected, serially diluted and plated onto MHA. Inoculated plates were then incubated at 37°C for 24 hr and the emergent colonies were counted. Excel software was employed to plot time-kill curves (CFU/ml vs time). Of note, synergy is defined as the bactericidal activity (≥ 2 log₁₀ difference in CFU/mL) of the combination as compared to the single agent after 24 hr of incubation (Betts et al., 2016).

Cytotoxicity assay

To investigate the percentage of cell survival following exposure to curcumin, cytotoxicity assay was carried out on human epithelial cell lines. To perform the cytotoxicity assay, human alveolar epithelial cells and fibroblast cells were cultured in RPMI 1640 medium (Biosera, USA) to which 1% L-glutamic acid, 10%

fetal bovine serum (FBS), 1% non-essential amino acid and 1% penicillin-streptomycin were added. Then, cells were incubated at 37°C in a CO₂-containing humidified atmosphere. For morphological and viability studies, at the point when the cells achieved 80% of conversion, they were seeded in 100 µl of complete medium into 96-well plates with 50,000 cells per well and, then incubated for 24 hr at 37°C with 5% CO₂ to allow for the attachment of cells to the surface. Subsequently, the wells were supplemented with selected concentrations of curcumin; following 24 hr of incubation, an Olympus IX70 inverted microscope was used to evaluate cells morphology. Moreover, the microtiter wells were supplemented with various concentrations of curcumin 136 to gauge mitochondrial functions of the cells after 24 hr of seeding. Then, the wells were directly supplemented with 20 µl of XTT [2,3-bis(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide]; after 4 hr of incubation in darkness, the absorbance at 570 nm was measure using a standard microplate reader (Anthos Labtec instruments) (Braydich-Stolle *et al.*, 2005).

Statistical Analysis

Chi-squared test was performed using SPSS 21 Software to check for any significant differences between datasets.

Results

Antibiotic susceptibility of clinical isolates

Fourteen clinical isolates collected from burn patients and four standard strains were used in this study. Antibiotic susceptibility tests showed that *P. aeruginosa* and *A. baumannii* isolates were resistant to all of the currently used antibiotics, including β-lactams (carbapenems and cephalosporins) aminoglycosides (gentamicin and amikacin), and fluoroquinolones (ciprofloxacin), yet remained susceptible to colistin. Three *K. pneumoniae* clinical isolates were found highly resistant to the

frequently used antibiotics, i.e. carbapenems (imipenem, meropenem, ertapenem, and doripenem), extended-spectrum cephalosporins (cefoxitin, ceftazidime, cefpodoxime, and cefotaxime), aminoglycoside (gentamicin and amikacin), fluoroquinolone (ciprofloxacin), and cotrimoxazole; three isolates were susceptible to fluoroquinolone (levofloxacin), tetracycline (minocycline and tigecycline), fosfomycin, and colistin.

Detection of carbapenemase-encoding genes

All the isolates were resistant to all β-lactam antibiotics including carbapenems. *P. aeruginosa* clinical isolates were extended-spectrum β-lactamases (ESBL) and metallo-β-lactamases (MBL) producing. Two *P. aeruginosa* isolates were IMP-producer and one isolate was VIM-producer. In addition, two isolates of *P. aeruginosa* were GES and VEB carbapenemases-producing. The global spread of *bla*_{NDM-1} genes among multidrug-resistant bacterial pathogens is a threat to human beings that affects all patients throughout the world (Bahramian *et al.*, 2019). In this study, three isolates of *K. pneumoniae* were NDM-producer.

Antibacterial activity of curcumin on clinical isolates

MIC levels ranged from 128 to 512 µg/ml for all clinical isolates and standard strains (Table 1). These results suggest that curcumin exhibits inhibitory effect on the growth of bacteria.

Effect of curcumin on antibiotic susceptibility

The effect of curcumin on antibiotic susceptibility was evaluated by measuring MIC levels of meropenem with and without a sub-inhibitory concentration of curcumin. Results showed that the MICs of meropenem were significantly reduced in the presence of curcumin (2- to 16-fold reductions), with synergy observed ($p \leq 0.05$) (Table 1).

Antibacterial activity of curcumin-meropenem combination

Table 1. Minimum inhibitory concentrations (MICs) of meropenem and curcumin alone or in combination and fractional inhibitory concentration indices (FICIs) for potentially important pathogens of burn wounds.

Isolate	Genes	Curcumin	meropenem	Curcumin-meropenem	FICI
		MIC ($\mu\text{g/ml}$)			
<i>K. pneumoniae</i>	DHA	128	128	32	0.5 (ad)
<i>P. aeruginosa</i>	VEB	128	128	32	0.5 (ad)
<i>A. baumannii</i>	OXA-23,OXA-24	128	64	16	0.37 (S)
<i>A. baumannii</i>	OXA-23,OXA-24	128	128	64	1 (ad)
<i>P. aeruginosa</i>	IMP-1	128	128	64	1 (ad)
<i>E. faecalis</i> ATCC 29212	Type strain	128	8	2	0.26 (S)
<i>P. aeruginosa</i>	GES	128	64	32	0.75 (ad)
<i>A. baumannii</i>	OXA-23,OXA-24	512	16	4	0.25 (S)
<i>A. baumannii</i> ATCC19606	Type strain	512	1	0.5	0.5 (ad)
<i>A. baumannii</i>	OXA-23,OXA-24	512	16	4	0.25 (S)
<i>P. aeruginosa</i>	IMP-1	512	128	8	0.064 (S)
<i>P. aeruginosa</i>	VIM-1	512	128	8	0.064 (S)
<i>E. coli</i> ATCC 25922	Type strain	256	0.025	0.01	0.4 (S)
<i>K. pneumoniae</i> ATCC 700603	Type strain	256	1	0.5	0.5 (ad)
<i>K. pneumoniae</i>	NDM-6	256	32	8	0.28 (S)
<i>K. pneumoniae</i>	NDM-1	256	32	16	0.56 (ad)
<i>K. pneumoniae</i>	NDM-6	256	32	16	0.56 (ad)
<i>P. aeruginosa</i>	IMP-2	256	32	16	0.56 (ad)

S = synergy, Ad = additive effect.

Synergism of curcumin with antibiotic susceptibility

In order to explore the interaction between curcumin and meropenem, checkerboard assay was accomplished to define the FIC indices for both carbapenem-associated multidrug-resistant isolates and also the type strain. FIC indices synergy between curcumin and meropenem ranged from 0.064 to 1 (Table 1). Additionally, to confirm the synergism of curcumin with the meropenem, time-killing assays were performed for *K. pneumoniae* positive for (*bla*_{NDM-1} gene). As shown in Figure 1, NDM-producing *K. pneumoniae* grew within 24 hr with inhibitory concentrations of meropenem alone and in combination with curcumin. However, over 99.99% of NDM-producing *K. pneumoniae* were killed within 24 hr with the same concentrations of both the meropenem and curcumin. These results imply that the

interaction of curcumin with meropenem is synergism ($p \leq 0.05$).

Cytotoxicity assay

Morphology of the cell lines was investigated after 24 hr of incubation with different concentrations of curcumin (256-512 $\mu\text{g/ml}$). The results showed that the human alveolar epithelial cells were well spread, and there was no distinct change in cell morphology after 24 hr of incubation with various concentrations of curcumin relative to control cells.




Figure 1. Time-kill curves plotted for meropenem and curcumin alone and in combination against *K. pneumoniae* (NDM).

Discussion

Broad spectrum antimicrobial resistance in MDR and XDR isolates significantly limited effective therapeutic options (Hirsch & Tam, 2010). The present study evaluated an alternative approach to treat the antibiotic-susceptible and -resistant Gram-positive (*E. faecalis*) and Gram-negative (*A. baumannii*, *E. coli*, *P. aeruginosa*, and *K. pneumoniae*) isolates associated with burn wound infections. As expected, the prevalence of carbapenem-associated multidrug-resistance among the clinical isolates in Iran was high. In this study, all of the isolates were resistant to carbapenems and the only effective antibiotic was colistin. Polymyxins are the last-resort options to treat carbapenem-associated multidrug-resistant isolates. Since the beginning of the 21st century, an increasing number of carbapenem-resistant clinical isolates has been reported around the world along with increasing reports on polymyxin-resistant isolates (Liu et al., 2016, Lee et al., 2017). Carbapenem- and polymyxin-associated multidrug-resistant isolates of *P. aeruginosa*, *K. pneumoniae* and *A. baumannii* are now common in Iran. Although a number of therapeutic options have been suggested to combat the carbapenem- and polymyxin-associated multidrug-resistant isolates (Menegucci et al., 2016), none of them has proven fully satisfactory for treating these extensively drug-resistant or pan-drug-resistant

isolates. *Curcuma longa* has been traditionally used in Asian countries as a medical herb due to its anti-inflammatory, antioxidant, antimicrobial, antimutagenic, and anticancer properties (Hewlings & Kalman, 2017). Curcumin has also been shown to have *in vitro* anti-microbial effects against a wide range of microorganisms including fungi as well as several Gram-negative and Gram-positive bacteria (Tyagi et al., 2015). Negi et al. reported that curcumins and curcuminoids possess better antibacterial activity against a wide range of microbes including *Staphylococcus aureus*, *Bacillus cereus*, *Bacillus subtilis*, *Bacillus coagulans*, *P. aeruginosa* and *E. coli* (Gul & Bakht, 2015). Karaman et al. showed that treatment of strains with MIC and sub-MIC concentrations of curcumin did not significantly increase the optical density of biofilm. The data obtained in our study supported the promising inhibitory effect of curcumin on *P. aeruginosa* biofilms (Karaman et al., 2013). In this study, minimum inhibitory concentrations of meropenem were significantly ($p \leq 0.05$) reduced in the presence of curcumin (2- to 32-fold reductions), with synergy observed. Combination therapy with different antibiotics has been used to combat *A. baumannii* infections. Kaur et al. showed that curcumin significantly decreased persistence against colistin. Hence, curcumin-colistin combination can be another option with anti-persister potential to control chronic *A. baumannii* infections (Kaur et al., 2018). Betts et al. reported the antimicrobial synergy between polymyxin E and curcumin and suggested that a combination of the two compounds could be used to treat or prevent traumatic wound infections of the skin (Betts et al., 2016). Another compound that has been found effective on *A. baumannii* in combination with meropenem, is epigallocatechin-3-gallate (EGCG). We confirmed the antibacterial activity of curcumin on carbapenem-associated multidrug-resistant

Antibacterial activity of curcumin-meropenem combination

clinical isolates, as shown by the MIC (256-512 µg/ml) of curcumin. These results are consistent with the notion that curcumin alone shows antibacterial activity on clinical isolates of *A. baumannii*, regardless of the presence of antibiotic resistance genes (Lee et al., 2017). In another study, Bansal et al. reported that curcumin alone and in combination with augmentin, could protect against pulmonary inflammation and acute lung injury generated during *K. pneumoniae* B5055-induced lung infection in BALB/c mice (Bansal & Chhibber, 2010). It was also found that curcumin synergistically increased *A. baumannii* susceptibility to meropenem in all tested carbapenem-associated multidrug-resistant isolates. Synergistic effect of curcumin on antibiotics in *A. baumannii* (Kaur et al., 2018) has been reported. The obtained results demonstrated that antibacterial activity of curcumin and its synergism with meropenem can sensitize carbapenem-associated multidrug-resistant isolates of *A. baumannii*, *P. aeruginosa*, and *K. pneumoniae*. Overall, we suggest that curcumin-antibiotic combinations may provide an alternative approach to treat infections with MDR and XDR bacteria regardless of antibiotic resistance.

Acknowledgment

This study was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences “IR.SBMU.MSP.REC.1397.749”, and was financially supported by research Department of the School of Medicine, Shahid Beheshti University of Medical Sciences (grant No. 15838).

Conflicts of interest

The authors declare that they have no conflict of interests.

References

- Bahramian A, Shariati A, Azimi T, Sharahi JY, Bostanghadiri N, Gachkar L, Ghalavand Z, Chirani AS, Erfanimanesh S, Hashemi A. 2019. First report of New Delhi metallo-β-lactamase-6 (NDM-6) among *Klebsiella pneumoniae* ST147 strains isolated from dialysis patients in Iran. *Infect Genet Evol*, 23:142-145.
- Bansal S, Chhibber S. 2010. Curcumin alone and in combination with augmentin protects against pulmonary inflammation and acute lung injury generated during *Klebsiella pneumoniae* B5055-induced lung infection in BALB/c mice. *J Med Microbiol*, 59: 429-437.
- Betts JW, Sharili AS, La Ragione RM, Wareham DW. 2016. In vitro antibacterial activity of curcumin-polymyxin B combinations against multidrug-resistant bacteria associated with traumatic wound infections. *J Nat Prod*, 79: 1702-1706.
- Braydich-Stolle L, Hussain S, Schlager JJ, Hofmann M-C. 2005. In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. *Toxicol Sci*, 88: 412-419.
- Chew KL, La M-V, Lin RT, Teo JW. 2017. Colistin and polymyxin B susceptibility testing for carbapenem-resistant and mcr-positive Enterobacteriaceae: comparison of Sensititre, MicroScan, Vitek 2, and Etest with broth microdilution. *J Med Microbiol*, 00268-00217.
- Chiu S-K, Ma L, Chan M-C, Lin Y-T, Fung C-P, Wu T-L, Chuang Y-C, Lu P-L, Wang J-T, Lin J-C. 2018. Carbapenem nonsusceptible *klebsiella pneumoniae* in taiwan: dissemination and increasing resistance of carbapenemase producers during 2012–2015. *Sci Rep*, 8: 8468.
- Church D, Elsayed S, Reid O, Winston B, Lindsay R. 2006. Burn wound infections. *Clin Microbiol Rev*, 19: 403-434.
- Fallah F, Noori M, Hashemi A, Goudarzi H, Karimi A, Erfanimanesh S, Alimehr S. 2014. Prevalence of blaNDM, blaPER, blaVEB, blaIMP, and blaVIM genes among *Acinetobacter baumannii* isolated from two hospitals of Tehran, Iran. *Scientifica*, 2014.
- Gul P, Bakht J. 2015. Antimicrobial activity of turmeric extract and its potential use in food industry. *Int J Food Sci Technol*, 52: 2272-2279.
- Gupta SC, Patchva S, Aggarwal BB. 2013. Therapeutic roles of curcumin: lessons learned from clinical trials. *AAPS J*, 15: 195-218.
- Hewlings S, Kalman D. 2017. Curcumin: a review of its' effects on human health. *Foods*, 6: 92.
- Hirsch EB, Tam VH. 2010. Impact of

- multidrug-resistant *Pseudomonas aeruginosa* infection on patient outcomes. *Expert Rev Pharmacoecon Outcomes Res*, 10: 441-451.
- Karaman M, Firinci F, Ayyildiz ZA, Bahar İH. 2013. *Pseudomonas aeruginosa* Suşlarında İmipenem, Tobramisin ve Curcuminin Biyofilm Oluşumu Üzerine Etkisi. *Mikrobiyol Bul*, 47: 192-194.
- Kaur A, Sharma P, Capalash N. 2018. Curcumin alleviates persistence of *Acinetobacter baumannii* against colistin. *Sci rep*, 8: 11029.
- Lee S, Al Razqan GS, Kwon DH. 2017. Antibacterial activity of epigallocatechin-3-gallate (EGCG) and its synergism with β -lactam antibiotics sensitizing carbapenem-associated multidrug resistant clinical isolates of *Acinetobacter baumannii*. *Phytomedicine*, 24: 49-55.
- Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis*, 16: 161-168.
- McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. 2013. Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae. *Antimicrob Agents Ch*, 57: 5131-5133.
- Menegucci TC, Albiero J, Migliorini LB, Alves JLB, Viana GF, Mazucheli J, Carrara-Marroni FE, Cardoso CL, Tognim MCB. 2016. Strategies for the treatment of polymyxin B-resistant *Acinetobacter baumannii* infections. *Int J Antimicrob Agents*, 47: 380-385.
- Mohammadi F, Goudarzi H, Hashemi A, Nojookambari NY, Khoshnood S, Sabzehali F. 2017. Detection of ISAbal in *Acinetobacter baumannii* strains carrying OXA genes isolated from Iranian burns patients. *Pediatr Infect Dis J*, 56:e39307.
- Suzuki S, Ohnishi M, Kawanishi M, Akiba M, Kuroda M. 2016. Investigation of a plasmid genome database for colistin-resistance gene *mcr-1*. *Lancet Infect Dis*, 16: 284-285.
- Tyagi P, Singh M, Kumari H, Kumari A, Mukhopadhyay K. 2015. Bactericidal activity of curcumin I is associated with damaging of bacterial membrane. *PLoS one*, 10: e0121313.
- Wayne P. 2012. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing. Twenty-second informational supplement. Document, M100-S22